Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.

Portfolio

Loading...
Select Portfolio and Asset Combination for Display on Market Band
Select Portfolio
Select Asset Class
Show More
Download ET MARKETS APP

Get ET Markets in your own language

DOWNLOAD THE APP NOW

+91

CHOOSE LANGUAGE

ENG

  • ENG - English
  • HIN - हिन्दी
  • GUJ - ગુજરાતી
  • MAR - मराठी
  • BEN - বাংলা
  • KAN - ಕನ್ನಡ
  • ORI - ଓଡିଆ
  • TEL - తెలుగు
  • TAM - தமிழ்
Drag according to your convenience
ET NOW RADIO
ET NOW
TIMES NOW

Glenmark Pharma gets USFDA nod for drug for patients on dialysis

The approved product is a generic version of Genzyme Corporation's Renagel tablets.

PTI|
Feb 11, 2019, 01.10 PM IST
0Comments
Agencies
pharma-agencies1
For the 12 months to December 2018, Renagel tablets market achieved annual sales of approximately USD 102.1 million, Glenmark said, citing IQVIA sales data. (Representative Image)
Glenmark Pharmaceuticals Monday said it has received final approval from the US health regulator for Sevelamer Hydrochloride tablets, used to control serum phosphorus in patients with chronic kidney disease on dialysis.

The approved product is a generic version of Genzyme Corporation's Renagel tablets.

"Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (USFDA) for Sevelamer Hydrochloride tablets in the strengths of 400 mg and 800 mg," the company said in a BSE filing.

For the 12 months to December 2018, Renagel tablets market achieved annual sales of approximately USD 102.1 million, Glenmark said, citing IQVIA sales data.

The company's current portfolio consists of 149 products authorised for distribution at the US marketplace and 53 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA.

The company's stock was trading at Rs 604.25, down 1.66 per cent, on BSE.
0Comments

Also Read

Lupin, Sun Pharma, Glenmark recall products in US

Glenmark Pharma gets USFDA nod for ear drops

New product launches will continue to drive growth: Glenn Saldanha, Glenmark

Stocks in the news: Emami, Jet Airways, ONGC, Adani Ports and Glenmark Pharma

Glenmark Q3 profit up 11% to Rs 116 crore

Comments
Add Your Comments
Commenting feature is disabled in your country/region.